Assessing speech disorders in patients treated for oral or oropharyngeal cancer
Validity of a Task of Acoustic-phonetic Decoding on Anatomic Deficits in Paramedical Assessment of Speech Disorders for Patients Treated for Oral or Oropharyngeal Cancer
This study is testing how well people who have been treated for oral or throat cancer can speak, using a special task to see if it helps understand their speech problems better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 116 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Marseille and 2 other locations) |
| Trial ID | NCT04742998 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate speech intelligibility in patients who have undergone treatment for oral or oropharyngeal cancer. It utilizes an acoustic-phonetic decoding task to objectively assess speech production and perception, bridging the gap between the two. The study hypothesizes that automatic processing of this task will provide reliable diagnostic insights into oropharyngeal deficits. Participants will be assessed based on their ability to produce isolated pseudo-words, with scores correlated to anatomical and functional speech deficits.
Who should consider this trial
Good fit: Ideal candidates include native French-speaking adults aged 18 and older who have been treated for oral or oropharyngeal cancer and are in clinical remission.
Not a fit: Patients with additional pathologies affecting speech or fluency disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools for assessing speech disorders in cancer patients, enhancing their rehabilitation.
How similar studies have performed: While the approach is innovative, similar studies have shown promise in using objective measures for speech assessment in oncology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged at least 18 years old and benefiting from a social security scheme * Native French-speaking patients * Patients treated for cancer of the oral cavity or oropharynx (surgical and / or radiotherapy and / or chemotherapy treatment) * Patients in clinical remission for at least 6 months (chronic nature and stability of the disorders) * All tumor sizes according to the tumor (T), node (N), and metastasis (M) categories (TNM classification) (T1 to T4) * Patients with a perceptible speech disorder in a conversational situation or not (to allow the determination of fine deficits) * Patients who do not object to carrying out the research Exclusion Criteria: * Patients with an associated pathology potentially responsible for speech or fluency disorders (joint, speech and language disorders of developmental, organic or functional origin, voice disorders of organic or functional origin, stammering , stammering, fluency disturbances, speech disturbances of neurological origin) * Patients reporting an auditory complaint and not having a hearing aid * Inability to provide the person with enlightened information and to ensure the subject's compliance because of impaired physical and / or psychological health, * Patients participating in another research including an exclusion period still in progress.
Where this trial is running
Marseille and 2 other locations
- AP- H Marseille - Hôpital de la Conception — Marseille, France (Recruiting)
- Institut universitaire du Cancer de Toulouse - Oncopole — Toulouse, France (Not_yet_recruiting)
- University Hospital Toulouse — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Clémence DEVOUCOUX — University Hospital, Toulouse
- Study coordinator: Clémence DEVOUCOUX
- Email: devoucoux.c@chu-toulouse.fr
- Phone: 06.50.72.24.85
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.